Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944408 | 0.90 | HTR4 (0.50) | HTR4CYP3A4HTR2CHTR3AHTR3E | |
| SCHEMBL1502018 | 0.76 | HTR4 (0.51) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7353994 | 0.75 | HTR4 (0.52) | HTR4CYP3A4HTR2CHTR3AHTR3E | |
| SCHEMBL505731 | 0.73 | HTR4 (0.36) | HTR4CYP3A4HTR2CHTR3AHTR3E | |
| SCHEMBL13091644 | 0.73 | ALDH1A1 (0.38) | CYP3A4LMNAPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL7395299 | 0.73 | HTT (0.33) | HTR4CYP3A4HTR3AHTR3EHTR3B | |
| SCHEMBL5316552 | 0.73 | HTR4 (0.47) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL31503642 | 0.72 | ALDH1A1 (0.39) | CYP3A4HTTPOLBTSHRALDH1A1 | |
| SCHEMBL24104857 | 0.72 | SMN1; SMN2 (0.40) | CYP3A4CYP2D6LMNATHRBNPSR1 | |
| SCHEMBL7751844 | 0.72 | HTR4 (0.50) | HTR4CYP3A4HTR2CHTR3AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8063070-B2 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-11-22 | — | — | US | disclosed |
| US-7790750-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A | 2007-02-15 | — | — | US | disclosed |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| US-6800628-B2 | SUCH AS (1-(2-((3-METHYL-2-PYRAZINYL)AMINO)ETHYL)-4-PIPERIDINYL)-METHYL-4-AMINO-5 -CHLORO-2,3-DIHYDRO-7-BENZOFURANCARBOXYLATE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-05 | — | — | US | disclosed |
| US-6509339-B2 | Gastrointestinal disorders; cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-21 | — | — | US | disclosed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | disclosed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | disclosed |
| EP-1206938-A1 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
| US-20020042430-A1 | Novel esters of 1, 4-disubstituted piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE (BE) | 2002-04-11 | — | — | US | disclosed |
| US-6291481-B1 | CONDITIONS RELATED TO A HAMPERED OR IMPAIRED GASTRIC EMPTYING AND MORE GENERALLY TO TREAT CONDITIONS RELATED TO A HAMPERED OR IMPAIRED GASTROINTESTINAL TRANSIT. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2001-09-18 | — | — | US | disclosed |
| EP-0991410-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999002156-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0885190-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997031897-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | HTR4 248/4885CYP3A4 442/4885HTR2C 75/4885 |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | HTR4 244/4885CYP3A4 424/4885HTR2C 71/4885 |
| US-20020042430-A1 | Novel esters of 1, 4-disubstituted piperidine derivatives | CBR1, ALK, ESRRA | HTR4 388/4885CYP3A4 392/4885HTR2C 206/4885 |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | HRH2, HRH4, GIPR | HTR4 565/4885CYP3A4 782/4885HTR2C 432/4885 |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | CBR1, ALK, CBR3 | HTR4 257/4885CYP3A4 684/4885HTR2C 137/4885 |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, SLC10A2, HRH4 | HTR4 389/4885CYP3A4 138/4885HTR2C 437/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | HTR4 407/4885CYP3A4 204/4885HTR2C 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.